Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) just unveiled an update.
Shanghai Haohai Biological Technology Co., Ltd. has announced its 2024 Annual General Meeting scheduled for June 10, 2025, where key resolutions will be considered, including the approval of the 2024 Annual Report, remuneration plans, and profit distribution. A significant proposal includes the abolishment of the Supervisory Committee and amendments to the Articles of Association and procedural rules, alongside granting the Board a mandate to repurchase H Shares, which could impact the company’s governance and shareholder value.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the biotechnology industry. It focuses on developing and providing biological products and technologies.
Average Trading Volume: 585,957
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.06B
See more insights into 6826 stock on TipRanks’ Stock Analysis page.